Tests in development for the Alere q include HIV, tuberculosis, and Ebola assays, and it will initially be targeted to low-resource settings in the developing world.
The Singapore-based molecular diagnostics firm continues to operate under court supervision while its finances get sorted out.
The firm, which went public in October, made a public offering of more than 2.5 million units at $8.80 per unit.
Among Canon BioMedical's life science projects is a genetic testing platform based on ultra-fast serial PCR and high-resolution melt analysis.
The firm said that it plans to list its stock on the Nasdaq under ticker symbol "RAIN" and added that its 2014 revenues were up 78 percent year over year to $30.6 million.
In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.
The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.
A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.
National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.